KANELLOPOULOS PANAGIOTIS-INRASTES

KANELLOPOULOS
PANAGIOTIS

Phd Candidate, Chemist

Lab: Molecular Radiopharmacy

KANELLOPOULOS PANAGIOTIS

Working experience:

25/07/2018 – : Postgraduate associate, programe: “Radiolabeled Vectors in Nuclear Oncology” (E-12224), NCSR “Demokritos”, project director: Maina–Nock Theodosia

Studies:

18/04/2019 – : PhD candidate, School of Medicine, University of Crete, supervisor: prof. Liapakis George. Lab of thesis elaboration: Molecular Radiopharmacy, INRASTES, NCSR “Demokritos”, Supervisor, Research Director: Maina–Nock Theodosia
May-June 2019: Educational seminar «6th international Lab Animal Course Crete 2019 FELASA accredited»
2014-16: MSc “Neuroscience”, School of Medicine, University of Crete
2008-14: Bachelor degree in Chemistry, Department of Chemistry, University of Crete

Foreign Languages:

English: Level 1 Certificate of English, University of Cambridge

Theses:

2016: Master Thesis, title: Subcloning the type 2 CRF receptor gene and pharmacological characterization of receptor. Lab: Molecular Pharmacology, Supervisor: Prof. Liapakis George
2013: Bachelor Thesis, title: Can the acquired drug resistance, of the protozoan parasite Leishmania, be maintained after passage in macrophages of the human cell line THP-1?. Lab: Laboratory of Clinical Bacteriology Parasitology Zoonoses and Geographical Medicine. Supervisor: Antoniou Maria, Professor in charge: Katerinopoulos HE

Publications in Peer-Review Scientific Journals: 9. Presentations in Scientific Meetings: 11

Link to Scopus:

https://www.scopus.com/results/results.uri?sort=plf-f&src=s&st1=Kanellopoulos&st2=Panagiotis&nlo=1&nlr=20&nls=afprfnm-t&affilName=NCSR+Demokritos&sid=f59263b53308d38b40d1b7d4c2dc6235&sot=anl&sdt=aut&sl=46&s=AU-ID%28%22Kanellopoulos%2c+Panagiotis%22+56500399600%29&partialQuery=&txGid=d87fd2f9ebfc35c9eb96bd96102b52f1

Selected Publications

Kanellopoulos, P., Kaloudi, A., de Jong, M., Krenning, E.P., Nock, B.A. and Maina, T., Key-protease inhibition regimens promote tumor targeting of neurotensin radioligands Pharmaceutics, Volume 12, Pages: 1-16, 2020 [doi]

Kaloudi, A., Kanellopoulos, P., Radolf, T., Chepurny, O.G., Rouchota, M., Loudos, G., Andreae, F., Holz, G.G., Nock, B.A. and Maina, T., Tc-DGA1, a Promising CCK2R-Antagonist-Based Tracer for Tumor Diagnosis with Single-Photon Emission Computed Tomography Molecular Pharmaceutics, Volume 17, Pages: 3116-3128, 2020 [doi]

Kanellopoulos, P., Lymperis, E., Kaloudi, A., de Jong, M., Krenning, E.P., Nock, B.A. and Maina, T., [99mTc]Tc-DB1 mimics with different-length PEG spacers: Preclinical comparison in GRPR-positive models Molecules, Volume 25, 2020 [doi]

Kanellopoulos, P., Nock, B.A., Krenning, E.P. and Maina, T., Optimizing the profile of [99mTc]Tc–Nt(7–13) tracers in pancreatic cancer models by means of protease inhibitors International Journal of Molecular Sciences, Volume 21, Pages: 1-14, 2020 [doi]

Kanellopoulos, P., Kaloudi, A., Rouchota, M., Loudos, G., de Jong, M., Krenning, E.P., Nock, B.A. and Maina, T., One step closer to clinical translation: Enhanced tumor targeting of [99mTc]Tc-DB4 and [111In]In-SG4 in mice treated with entresto Pharmaceutics, Volume 12, Pages: 1-14, 2020 [doi]

Selected Grants

Radiolabeled Vectors in Nuclear Oncology

2018-2023 | Cyclotron Rotterdam BV

The research project “Radiolabeled Vectors in Nuclear Oncology” coded Ε12224 with a 5-year duration (2018-2023) is coordinated by Dr. T. Maina-Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with Cyclotron Rotterdam BV, Erasmus, MC, Rotterdam, The Netherlands. The latter...

New SST₂R-antagonists in the diagnosis of neuroendocrine tumors with PET/CT

2020-2022 | ICPO Academy

The research project “New SST₂R-antagonists in the diagnosis of neuroendocrine tumors with PET/CT” coded Ε12452 with a 1-year duration (2020-2022) is coordinated by Dr. T. Maina-Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with the Department of Chemistry, ...

Development of Radiometalated GRPR-Antagonists for Tumor Diagnosis and Therapy

2014-2016 | Advanced Accelerator Applications

The research project “Development of Radiometalated GRPR-Antagonists for Tumor Diagnosis and Therapy” coded Ε11902 with a 3-year duration (2014-2016) is coordinated by Dr. T. Maina-Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with the Nuclear Medicine & Radiology ...

Improved Tumor Targeting with Radiolabeled Peptidomimetics

2018-2022 | Ludwig Boltzmann Institute Applied Diagnostics/Austrian Science Foundation (FWF)

The research project “Improved Tumor Targeting with Radiolabeled Peptidomimetics” with a 5-year duration (2018-2023) is coordinated by Dr. B. A. Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with the Ludwig Boltzmann Institute Applied Diagnostics, sponsored by Austrian...

KANELLOPOULOS PANAGIOTIS